Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset

Vera Therapeutics, Inc.’s immunoglobulin A nephropathy (IgAN) asset, atacicept, has shown enhanced potential in a new prespecified per-protocol (PP) analysis from its Phase II ORIGIN trial, prompting the firm to pause other programs and redouble efforts in the renal disease.

Earlier this month, topline data were released from the ORIGIN intent-to-treat (ITT) population of 116 patients in which a pooled analysis of the 75mg/150mg doses showed atacicept achieved a mean...